Market Performance
Closing price (10:05 PM Central Europe, Tuesday 20th)
Adagene (ADAG) traded up 11.17 % during the 24‑hour period.
Current trading price: USD 2.50 per share.
Share metrics
Shares outstanding: 67.1 million.
Market capitalization: USD 138.3 million.
24‑hour trading volume: USD 707.2 k.
Historical trend
Since the end of the previous month, the stock has declined 28.66 %.
200‑day simple moving average: USD 3.39.
52‑week high: USD 4.85 (recorded 07/01/2026).
52‑week low: USD 1.30 (recorded 11/07/2025).
Analyst Outlook
Equity coverage
HC Wainwright maintains a buy recommendation with a target price of $7.00.
Current share price is $2.06.
Ownership and institutional interest
Insider transactions indicate increased executive ownership.
Renaissance Technologies and other institutional investors have acquired positions, signaling continued interest in the company’s antibody‑based oncology platform.
Technology platform
Adagene’s pipeline incorporates NEObody and SAFEbody technologies.
The platform is positioned to develop novel cancer immunotherapies, aligning with broader precision oncology trends noted in recent market reports.
Strategic focus
Analysts monitor progress in pipeline development and expansion of commercial opportunities.
Related Stocks – 24‑Hour Performance
| Symbol | Trade Direction | Current Price | Market Capitalization | P/E Ratio |
|---|---|---|---|---|
| Jin Medical (ZJYL) | +1.44 % | USD 2.04 | USD 163.2 million | 13.75 |
| Cloud Factory Hol (2512.HK) | 0 % | HKD 2.69 | HKD 1.3 bn | – |
| Pw Medtech (1358.HK) | –0.55 % | HKD 0.90 | HKD 1.3 bn | 26.78 |
| Powerlong Commercial Management (9909.HK) | 0 % | HKD 1.99 | HKD 1.3 bn | 5.53 |
| Immuneonco Biopharmaceutical (1541.HK) | +2.58 % | HKD 2.97 | HKD 1.3 bn | – |
Company Overview
Adagene Inc. is a biotechnology company focused on developing therapeutic antibodies for cancer treatment. The company operates in both the United States and China, providing services to patients with various malignancies.